Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) | MicrobiomeTrials← Back to trialsNCT02935517
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
UNKNOWNPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2017-08-03Est. Completion: 2022-08
Enrollment target: 24 participants Locations- VitreoRetinal Associates, Gainesville, Florida, United States
- Bascom Palmer Eye Institute, Miami, Florida, United States
- Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
- Cincinnati Eye Institute, Cincinnati, Ohio, United States
- Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon, United States
- Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Other microbiome trials you might be interested in
ACHROMATOPSIA 7Achromatopsia
Some patients with achromatopsia, an inherited disorder characterized by partial or complete loss of color vision, carry…
New York, United StatesCompleted Aug 2027
Inherited Retinal Diseases
The purpose of this study is to better understand the natural history of Inherited Retinal Disease (IRD) and help inform…
Birmingham, United StatesCompleted Jul 2, 2026
Recruiting
Inherited Ophthalmic DiseasesHypopigmentation DisorderCorneal DystrophyBlue-cone MonochromacyBest DiseaseAniridiaAlbinism
Background:
The eyeGENE (Registered Trademark) program is a research resource for inherited eye conditions which includ…
Bethesda, United StatesEst. completion Jun 27, 2054